March 3, 2026Open Access

Evaluation of NETosis Inhibitors in a Laboratory-Developed ex-vivo Human Neutrophil Model

Key Points

NETosis inhibitors demonstrate a promising impact on neutrophil function in the examined ex-vivo model.
The analysis utilized a laboratory-developed ex-vivo human neutrophil model to assess the effects.
Investigation focused on pharmacological agents aiming to inhibit NETosis processes in neutrophils.
Findings may indicate new therapeutic approaches for conditions involving neutrophil activation.

Abstract

Constant Gillot,1 Pauline Michaux,1 Jonathan Decarpentrie,1 Romane Vandamme,1 Jean-Michel Dogné,1 Julien Favresse,1,2 Jonathan Douxfils1,3 1Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, University of Namur, Namur, 5000, Belgium; 2Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, 5000, Belgium; 3Qualiblood s.a., Research and Development Department, Liège, 4000, BelgiumCorrespondence: Constant Gillot, Email constant.gillot@unamur.be

Evaluation of NETosis Inhibitors in a Laboratory-Developed ex-vivo Human Neutrophil Model

Key Points

Abstract

Cite This Study